---
document_datetime: 2024-12-19 12:14:52
document_pages: 11
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/carbaglu-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
document_name: carbaglu-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
version: success
processing_time: 6.9392166
conversion_datetime: 2025-12-28 20:04:36.822957
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Carbaglu

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                                                                                                                                                                 | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| IAIN/0046/G          | This was an application for a group of variations. B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - | 09/12/2024                          |                                             | SmPC, Annex II, Labelling and PL |           |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

|           | Not including batch control/testing A.1 - Administrative change - Change in the name and/or address of the MAH                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |            |            |                       |                                                                                                                                                                                                                |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0045   | Update of sections 4.2, 4.4 and 5.2 of the SmPC in order to include a proposed dose adjustment for patients with impaired renal function based on final results from study RCD-P0-027; this is a Phase I, multicenter, open-label, parallel-group adaptive pharmacokinetic single dose study of oral Carbaglu in subjects with normal and varying degrees of impaired renal function. The Package Leaflet is updated accordingly. The RMP version 2.3 has also been submitted. In addition, the MAH took the opportunity to implement editorial changes in Annex II and Labelling, and to bring the PI in line with the latest QRD template version 10.3. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance | 22/06/2023 | 05/07/2024 | SmPC, Annex II and PL | Based on the review of the data, the CHMP concluded that the dose of Carbaglu must be reduced in patients with renal impairment. For more information, please refer to the Summary of Product Characteristics. |
| IA/0043/G | This was an application for a group of variations. A.7 - Administrative change - Deletion of manufacturing sites B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 19/03/2021 | n/a        |                       |                                                                                                                                                                                                                |
| IA/0042   | B.II.e.1.a.1 - Change in immediate packaging of the finished product - Qualitative and quantitative                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 27/10/2020 | n/a        |                       |                                                                                                                                                                                                                |

<div style=\"page-break-after: always\"></div>

|                   | composition - Solid pharmaceutical forms                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |            |            |                                  |                                   |
|-------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|-----------------------------------|
| PSUSA/564/2 02001 | Periodic Safety Update EU Single assessment - carglumic acid                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 01/10/2020 | n/a        |                                  | PRAC Recommendation - maintenance |
| IG/1085/G         | This was an application for a group of variations. A.1 - Administrative change - Change in the name and/or address of the MAH A.5.a - Administrative change - Change in the name and/or address of a manufacturer/importer responsible for batch release A.5.a - Administrative change - Change in the name and/or address of a manufacturer/importer responsible for batch release A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites | 16/05/2019 | 23/04/2020 | SmPC, Annex II, Labelling and PL |                                   |
| N/0039            | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                                                                                                                          | 22/02/2019 | 23/04/2020 | PL                               |                                   |
| N/0037            | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                                                                                                                          | 04/07/2018 | 23/04/2020 | Labelling and PL                 |                                   |
| IAIN/0036         | B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site                                                                                                                                                                                                                                                                                                                                                                                                                                        | 22/05/2018 | n/a        |                                  |                                   |
| IB/0035           | B.I.a.2.e - Changes in the manufacturing process of the AS - Minor change to the restricted part of an                                                                                                                                                                                                                                                                                                                                                                                                                                    | 15/05/2018 | n/a        |                                  |                                   |

<div style=\"page-break-after: always\"></div>

|           | ASMF                                                                                                                                                                                                                                                                                                                                                                                                    |            |            |                                  |                      |
|-----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|----------------------|
| IA/0034   | B.II.b.4.a - Change in the batch size (including batch size ranges) of the finished product - Up to 10-fold compared to the originally approved batch size                                                                                                                                                                                                                                              | 21/02/2018 | n/a        |                                  |                      |
| IA/0033/G | This was an application for a group of variations. B.I.a.3.a - Change in batch size (including batch size ranges) of AS or intermediate - Up to 10-fold increase compared to the originally approved batch size B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.I.c.1.a - Change in immediate packaging of the AS | 08/12/2017 | n/a        |                                  | - Qualitative and/or |
| IB/0032   | B.II.f.1.b.2 - Stability of FP - Extension of the shelf life of the finished product - After first opening (supported by real time data)                                                                                                                                                                                                                                                                | 08/09/2017 | 11/01/2018 | SmPC, Annex II, Labelling and PL |                      |
| IG/0773/G | This was an application for a group of variations. B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing            | 14/02/2017 | 11/01/2018 | Annex II and PL                  |                      |

<div style=\"page-break-after: always\"></div>

| IAIN/0030         | B.II.b.1.b - Replacement or addition of a manufacturing site for the FP - Primary packaging site                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 16/12/2016   | n/a        |                        |                                                                                                                                                                 |
|-------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IG/0686           | B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 12/05/2016   | n/a        |                        |                                                                                                                                                                 |
| PSUSA/564/2 01501 | Periodic Safety Update EU Single assessment - carglumic acid                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 24/09/2015   | 19/11/2015 | SmPC, Labelling and PL | Please refer to Carbaglu PSUSA/00000564/201501 EPAR: Scientific conclusions and grounds recommending the variation to the terms of the marketing authorisation. |
| IB/0027/G         | This was an application for a group of variations. B.II.e.1.a.1 - Change in immediate packaging of the finished product - Qualitative and quantitative composition - Solid pharmaceutical forms B.II.e.1.a.1 - Change in immediate packaging of the finished product - Qualitative and quantitative composition - Solid pharmaceutical forms B.II.e.2.b - Change in the specification parameters and/or limits of the immediate packaging of the finished product - Addition of a new specification parameter to the specification with its corresponding test method B.II.e.2.b - Change in the specification parameters and/or limits of the immediate packaging of the finished product - Addition of a new specification parameter to the specification with its corresponding test method | 19/08/2015   | 19/11/2015 | SmPC and PL            |                                                                                                                                                                 |

<div style=\"page-break-after: always\"></div>

|           | limits of the immediate packaging of the finished product - Addition of a new specification parameter to the specification with its corresponding test method B.II.e.4.a - Change in shape or dimensions of the container or closure (immediate packaging) - Non- sterile medicinal products B.II.e.4.a - Change in shape or dimensions of the container or closure (immediate packaging) - Non- sterile medicinal products B.II.e.6.a - Change in any part of the (primary) packaging material not in contact with the finished product formulation - Change that affects the product information B.II.e.7.b - Change in supplier of packaging components or devices (when mentioned in the dossier) - Replacement or addition of a supplier   |            |            |    | and/or   |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----|----------|
| N/0025    | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 31/03/2015 | 19/11/2015 | PL |          |
| IG/0535   | C.I.8.a - Introduction of or changes to a summary of Pharmacovigilance system - Changes in QPPV (including contact details) and/or changes in the PSMF location                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 06/03/2015 | n/a        |    |          |
| IB/0023/G | This was an application for a group of variations. B.II.b.1.b - Replacement or addition of a manufacturing site for the FP - Primary packaging site B.II.b.1.e - Replacement or addition of a                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 25/06/2014 | n/a        |    |          |

<div style=\"page-break-after: always\"></div>

|         | manufacturing site for the FP - Site where any manufacturing operation(s) take place, except batch- release, batch control, primary and secondary packaging, for non-sterile medicinal products B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place B.II.b.4.a - Change in the batch size (including batch size ranges) of the finished product - Up to 10-fold compared to the originally approved batch size B.II.b.5.b - Change to in-process tests or limits applied during the manufacture of the finished product - Addition of a new test(s) and limits   |            |            |                 |
|---------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------|
| IG/0393 | C.I.8.a - Introduction of or changes to a summary of Pharmacovigilance system - Changes in QPPV (including contact details) and/or changes in the PSMF location                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 20/12/2013 | n/a        |                 |
| IG/0392 | B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 19/12/2013 | 07/05/2014 | Annex II and PL |
| II/0020 | To introduce an alternative manufacturer of the active substance supported by an active substance master file. B.I.a.1.b - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS -                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 19/09/2013 | n/a        |                 |

<div style=\"page-break-after: always\"></div>

|           | of a new manufacturer of the AS that is by an ASMF                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |            |            |          | Introduction supported   |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------|--------------------------|
| IB/0018   | B.II.f.1.b.1 - Stability of FP - Extension of the shelf life of the finished product - As packaged for sale (supported by real time data)                                                                                                                                                                                                                                                                                                                                                                                                                         | 24/04/2013 | 07/05/2014 | SmPC     |                          |
| IA/0019   | A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 19/02/2013 | n/a        |          |                          |
| N/0017    | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 31/08/2012 | 07/05/2014 | PL       |                          |
| IA/0016   | C.I.9.a - Changes to an existing pharmacovigilance system as described in the DDPS - Change in the QPPV                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 15/08/2011 | n/a        | Annex II |                          |
| IB/0015/G | This was an application for a group of variations. B.II.b.1.e - Replacement or addition of a manufacturing site for the FP - Site where any manufacturing operation(s) take place, except batch- release, batch control, primary and secondary packaging, for non-sterile medicinal products B.II.b.1.b - Replacement or addition of a manufacturing site for the FP - Primary packaging site B.II.b.2.a - Change to batch release arrangements and quality control testing of the FP - Replacement or addition of a site where batch control/testing takes place | 02/08/2011 | n/a        |          |                          |

<div style=\"page-break-after: always\"></div>

| II/0013   | This variation concerns an extension of indication of Carbaglu to add the treatment of hyperammoniemia due to isovaleric acidaemia, methylmalonic acidaemia and propionic acidaemia. The Package Leaflet has been amended accordingly. In addition the MAH also took opportunity to bring the SmPC, Package Leaflet and Labelling in line with the latest QRD template and to update contact details of local representatives. C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one                                                                                          | 14/04/2011   | 27/05/2011   | SmPC, Labelling and PL   | The scientific discussion of the CHMP assessment report will be published.   |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|--------------------------|------------------------------------------------------------------------------|
| IB/0014/G | This was an application for a group of variations. B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate B.II.d.2.d - Change in test procedure for the finished product - Other changes to a test procedure (including replacement or addition) B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation B.II.d.1.z - Change in the specification parameters and/or limits of the finished product - Other variation | 15/04/2011   | n/a          |                          |                                                                              |
| IA/0012   | IA_39_Change/addition of imprints, bossing or other markings                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 21/09/2009   | n/a          | SmPC                     |                                                                              |

<div style=\"page-break-after: always\"></div>

|                |                                                                                                                                                                    |                       |                |                                                         | Based on the review of the available information the CHMP                                                                                                                                                                                                                                                                                  |
|----------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------|----------------|---------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| R/0011 IA/0010 | Renewal of the marketing authorisation. IA_01_Change in the name and/or address of the marketing authorisation holder IA_05_Change in the name and/or address of a | 24/01/2008 24/09/2007 | 20/05/2008 n/a | SmPC, Labelling and PL SmPC, Annex II, Labelling and PL | is of the opinion that the quality, the safety and the efficacy of this medicinal product continues to be adequately and sufficiently demonstrated and therefore considers that the benefit/risk profile of Carbaglu continues to be favourable. The CHMP was also of the opinion that the renewal can be granted with unlimited validity. |
| IA/0009        | IA_07_a_Replacement/add. of manufacturing site: Secondary packaging site                                                                                           | 18/06/2007            | n/a            |                                                         |                                                                                                                                                                                                                                                                                                                                            |
| S/0008         | Annual re-assessment.                                                                                                                                              | 27/04/2006            | 26/06/2006     | Annex II                                                | Since all specific obligations stated in Annex II.C of the Opinion dated 21 April 2005 have been fulfilled, there are no remaining grounds for the Marketing Authorisation to remain under exceptional circumstances.                                                                                                                      |
| II/0006        | Update of Summary of Product Characteristics                                                                                                                       | 17/03/2005            | 27/04/2005     | SmPC                                                    | Udate in section 5.2 of the Summary of Product Characteristics, further to the completion of the clinical study on the disposition of radiolabelled carglumic acid in three healthy volunteers.                                                                                                                                            |
| II/0005        | Update of Summary of Product Characteristics and Package Leaflet                                                                                                   | 17/03/2005            | 27/04/2005     | SmPC and PL                                             | Udate to sections 4.3, 4.6 and 5.3 of the Summary of Product Characteristics (SPC) and section 2 of the Package Leaflet (PL) with the results of the reproduction toxicology study program, in compliance with the CHMP conclusions on the first annual reassessment.                                                                      |

<div style=\"page-break-after: always\"></div>

| S/0007   | Annual re-assessment.                                                                    | 21/04/2005   | 21/04/2005   |                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
|----------|------------------------------------------------------------------------------------------|--------------|--------------|------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0004  | IB_41_a_02_Change in pack size - change in no. of units outside range of appr. pack size | 07/12/2004   | 07/12/2004   | SmPC, Labelling and PL |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| IB/0003  | IB_42_a_01_Change in shelf-life of finished product - as packaged for sale               | 27/09/2004   | n/a          | SmPC                   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| S/0001   | Annual re-assessment.                                                                    | 03/06/2004   | 21/09/2004   | Annex II and PL        | The CHMP reviewed the evidence of compliance with the Specific obligations submitted by the MAH and re-assessed the benefit/risk profile for Carbaglu. On the basis of the data submitted since the Marketing Authorisation, the benefit/risk for Carbaglu in the treatment of hyperammonaemia due to N-acetylglutamate synthase deficiency remained positive. The CHMP therefore recommended the updating of the Community Marketing Authorisation for Carbaglu and that the authorisation should remain under exceptional circumstances. |
| IA/0002  | IA_11_a_Change in batch size of active substance or intermediate - up to 10-fold         | 05/07/2004   | n/a          |                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |